NCT01061944已完成不适用
Biopsies of Cancer Patients for Tumor Molecular Characterization
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 188
- 试验地点
- 1
- 主要终点
- To determine the feasibility and safety of repeat biopsies for molecular characterization.
研究概览
简要总结
In this research study, we are looking at performing a repeat biopsy of patients' tumors, even though they have already been diagnosed with cancer. The tumor tissue obtained from the biopsy will be studied to see what it looks like at the molecular (genetic) level. By conducting this study, we hope to learn more about how cancers work, why cancers respond to certain treatments, and how they become resistant to certain treatments. We also hope to demonstrate that biopsies like this can be performed safely in large numbers of patients. The research done on the tumor samples may help us identify which patients in the future are most likely to respond to new cancer therapies.
详细描述
- In order to participate in this research study, participants must have already been diagnosed with cancer. The cancer must be located in a part of the body that is accessible for a biopsy and the doctor that will perform the biopsy must agree that the participant is a good candidate for biopsy. The biopsy will be done in the usual way, as part of your standard medical care.
- After the biopsy, the participant will return to the clinic approximately one week later for a check on their status. At this visit participants will be asked questions about your post-biopsy health. We will continue to follow-up with the participants by phone or at subsequent clinic visits for one month following the biopsy.
- The biopsy obtained will be studied in the Translational Research Laboratory at Massachusetts General Hospital, where it will undergo a panel of genetic tests. These tests look to find out what is driving the cancer or making it tick. It is important to understand that the genetic tests we will do include a number of cancer related genes or proteins that may be important for making treatment decisions, either now or in the future. The test results may or may not show a finding that could affect the participant's treatment options. There will be no specific testing done for inherited genetic abnormalities, so undergoing this research will not give information about the risk of cancer for people in the participant's family.
- If there is left-over tissue from biopsy, it will also be used to try to discover new findings about how cancers respond or become resistant to cancer treatments. These experiments will include trying to grow the cancer cells in a petri dish in the lab or trying to grow the cancer cells inside research mice to learn more about how the cancer works. This portion of the testing os part of the research study and is considered experimental, so the results will not be entered into the participants' medical record.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must already be known to have metastatic, incurable cancer.
- •Patients must have been referred for repeat tumor biopsy as part of standard care and biopsy must have been approved by the appropriate biopsy service (interventional radiology or surgery). Such approval includes review of medical history and laboratory parameters as per standard care.
- •18 years of age or older
- •Patients must have previously responded to a molecularly-targeted therapy and subsequently developed resistance, or have an analogous clinical situation in which determining their molecular genotype is of interest clinically and/or scientifically.
- •No specific exclusion criteria.
排除标准
- 未提供
结局指标
主要结局
To determine the feasibility and safety of repeat biopsies for molecular characterization.
时间窗: 2 years
次要结局
- To determine the somatic genotype of cancer patients with acquired resistance to a targeted therapy, and to compare these findings with pre-treatment genomic profiled from the same patients.(2 years)
- To estimate the success rate of molecular diagnostics from biopsies specifically obtained for such testing.(2 years)
研究者
Lecia V. Sequist
Principal Investigator
Massachusetts General Hospital
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Prospective Comprehensive Molecular Profiling In Neuroendocrine TumorsNeuroendocrine TumorsPancreatic Neuroendocrine TumorsNCT02586844University Health Network, Toronto13
已完成
不适用
Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With ChemotherapyEstrogen ReceptorHer-2PgrBreast CancerNCT00897299Eastern Cooperative Oncology Group900
招募中
2 期
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerER+ Breast CancerHER2-negative Breast CancerNCT04985266Royal Marsden NHS Foundation Trust1,100
已完成
不适用
Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and ChemotherapyColorectal CancerNCT00918827Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan2,128
进行中（未招募）
不适用
Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or ImmunotherapyCancerNCT03835520Cliniques universitaires Saint-Luc- Université Catholique de Louvain200